Design, synthesis, and structure - Activity relationship of N-arylnaphthylamine derivatives as amyloid aggregation inhibitors

Journal of Medicinal Chemistry

Volumn 55, Issue 19, 2012, Pages 8538-8548

  Di Santo, Roberto ^a   Costi, Roberta ^a   Cuzzucoli Crucitti, Giuliana ^a   Pescatori, Luca ^a   Rosi, Federica ^a   Scipione, Luigi ^a   Celona, Diana ^b   Vertechy, Mario ^b   Ghirardi, Orlando ^b   Piovesan, Paola ^b   Marzi, Mauro ^b   Caccia, Silvio ^c   Guiso, Giovanna ^c   Giorgi, Fabrizio ^b   Minetti, Patrizia ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Sigma Tau SpA   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

(1 METHOXY 2 NAPHTHYL) PHENYLAMINE; 1 METHOXY 4[(4 METHOXYPHENYL) THIO] NAPHTHALENE; 2 METHOXY 5(4 METHOXY 1 NAPHTHYLAMINO) BENZOIC ACID; 2 METHOXY N (2 METHOXY 1 NAPHTHYL) NAPHTHALEN 1 AMINE; 4 FLUORO N (4 FLUOROPHENYL) NAPHTHALEN 1 AMINE; 4 FLUORO N [4 (METHYLTHIO) PHENYL] NAPHTHALEN 1 AMINE; 4 METHOXY N (4 METHOXYPHENYL) 1 NAPHTHALENAMINE; 4 METHOXY N PHENYL 1 NAPHTHALENAMINE; 4 PHENYLAMINO NAPHTHALEN 1 OL; 4(1 METHOXY 2 NAPHTHYLAMINO) BENZOIC ACID; 4(1 NAPHTHYLAMINO) BENZOIC ACID; 4(4 HYDROXY 1 NAPHTHYLAMINO) BENZOIC ACID; 4(4 METHOXY 1 NAPHTHYLAMINO) BENZOIC ACID; AMYLOID BETA PROTEIN[1-42]; COLLAGEN FIBRIL; METHYL 2 (METHOXYMETHYL) 5[(4 METHOXYNAPHTHALEN 1 YL) AMINO] BENZOATE; METHYL 2[(2 METHOXY 1 NAPHTHYL) AMINO] BENZOATE; METHYL 4(1 METHOXY 2 NAPHTHYLAMINO) BENZOATE; METHYL 4(1 NAPHTHYLAMINO) BENZOATE; METHYL 4(4 HYDROXY 1 NAPHTHYLAMINO) BENZOATE; METHYL 4[(4 METHOXYNAPHTHALEN 1 YL) AMINO] BENZOATE; N (4 IODOPHENYL) 1 METHOXYNAPHTHALEN 2 AMINE; N (4 METHOXY 1 NAPHTHYL) N (2 METHOXYPHENYL) AMINE; N (4 METHOXYPHENYL) 4 NITRONAPHTHALEN 1 AMINE; N (5 IODO 2 METHOXYPHENYL) N (4 METHOXY) 1 NAPHTHYLAMINE; N ARYLNAPHTHYLAMINE DERIVATIVE; N,N DIMETHYL N' [4 (METHYLTHIO) PHENYL] NAPHTHALENE 1,4 DIAMINE; NAPHTHALENE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD LEVEL; BRAIN LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; FIBER; IC 50; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PROTEIN AGGREGATION; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

AMYLOID; AMYLOID BETA-PEPTIDES; ANIMALS; BLOOD-BRAIN BARRIER; DRUG DESIGN; MICE; NAPHTHALENES; PEPTIDE FRAGMENTS; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 84867382314     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301105m     Document Type: Article

References (34)

1. World Alzehimer Report 2010; Alzehimer's Disease International: London, 2010.
2. Chen, M. The Alzheimer's plaques, tangles and memory deficits may have a common origin. Part II: therapeutic rationale Front. Biosci. 1998, 3, a32-a37
3. Billings, L. M.; Oddo, S.; Green, K. N.; McGaugh, J. L.; LaFerla, F. M. Intraneuronal Aβ causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice Neuron 2005, 45, 675-688
4. Okamura, N.; Suemoto, T.; Furumoto, S.; Suzuki, M.; Shimadzu, H.; Akatsu, H. Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease J. Neurosci. 2005, 25, 10857-10862
5. Sair, H. I.; Doraiswamy, P. M.; Petrella, J. R. In vivo amyloid imaging in Alzheimer's disease Neuroradiology 2004, 46, 93-104
6. Mathis, C. A.; Klunk, W. E.; Price, J. C.; DeKosky, S. T. Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies Arch. Neurol. 2005, 62, 196-200
7. Villemagne, V. L.; Rowe, C. C.; Macfarlane, S.; Novakovic, K. E.; Masters, C. L. Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease J. Clin. Neurosci. 2005, 12, 221-230
8. Lorenzo, A.; Yankner, B. A. 8-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 12243-12247
9. Frandrich, M. On the structural definition of amyloid fibrils and other polypeptides aggregates Cell. Mol. Life Sci. 2007, 64, 2066-2078
10. Iverfeldt, K.; Walaas, S. I.; Greengard, P. Altered processing of Alzheimer amyloid precursor protein in response to neuronal degeneration Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 4146-4150
11. Masters, C. L.; Cappai, R.; Barnham, K. J.; Villemagne, V. L. Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics J. Neurochem. 2006, 97, 1700-1725
12. Galimberti, D.; Scarpini, E. Alzheimer's disease: from pathogenesis to disease-modifying approaches CNS Neurol. Disord.: Drug Targets 2011, 10, 163-174
13. Glabe, C. C. Amyloid accumulation and pathogensis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Abeta Subcell. Biochem. 2005, 38, 167-177
14. Re, F.; Airoldi, C.; Zona, C.; Masserini, M.; La Ferla, B.; Quattrocchi, N.; Nicotra, F. Beta amyloid aggregation inhibitors: small molecules and candidate drugs for therapy of Alzehimer's disease Curr. Med. Chem. 2010, 17, 2990-3006
15. Sabbagh, M. N.; Galasko, D.; Thal, L. J. Amyloid-beta and treatment opportunities for Alzheimer's disease J. Alzheimer's Dis. 2000, 2, 231-259
16. Rogers, J. Y.; Lahiri, D. K. Metal and inflammatory target for Alzheimer's disease Curr. Drug Targets 2004, 5, 535-551
17. Dodel, R. C.; Hampel, H.; Du, Y. Immunotherapy for Alzheimer's disease Lancet Neurol. 2003, 2, 215-220
18. Levine, H., III. Small molecules inhibitors of Aβ assembly Amyloid 2007, 14, 185-197
19. Gisponer, J.; Haberthur, U.; Caflisch, A. The role of side-chain interactions in the early steps of aggregation: molecular dynamics simulations of an amyloid-forming peptide from the yeast prion Sup35 Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 5154-5159
20. Hills, R. D., Jr.; Brooks, C. L., III. Hydrophobic cooperativity as a mechanism for amyloid nucleation J. Mol. Biol. 2007, 368, 894-901
21. Covertino, M.; Pellarin, R.; Catto, M.; Carotti, A.; Caflish, A. 9,10-Anthraquinone hinders beta-aggregation: How does a small molecule interfere with Abeta-peptide amyloid fibrillation? Protein Sci. 2009, 18, 792-800
22. Zheng, J.; Ma, B.; Nussinov, R. Consensus features in amyloid fibrils: sheet-sheet recognition via a (polar or nonpolar) zipper structure Phys. Biol. 2006, 3, 1-4
23. Keowkase, R.; Luo, Y. Mechanism of CNS drugs and their combinations for Alzheimer's disease Cent. Nerv. Syst. Agents Med. Chem. 2008, 8, 241-248
24. Le Vine, H., III. Stopped-flow kinetics reveal multiple phases of thioflavin T binding to Alzheimer β(1-40) amyloid fibrille Arch. Biochem. Biophys. 1997, 342, 306-316
25. Le Vine, H., III. Thioflavin T. interaction with synthetic Alzheimer's disease β-amyloid peptide: detection of amyloid aggregation in solution Protein Sci. 1993, 2, 404-410
26. Kimler, B. F.; Rethorst, R. D.; Cox, G. G. Investigation of the interaction of cardiotoxic anticancer agents using the fetal mouse heart organ culture system Invest. New Drugs 1986, 4, 127-133
27. Simons, L. J.; Caprathe, B. W.; Callahan, M.; Graham, J. M.; Rimura, T.; Lai, Y.; LeVine, H., III; Lipinski, W.; Sakkab, A. T.; Tasaki, Y.; Walzer, L. C.; Yasunaga, T.; Ye, Y.; Zhuang, N.; Augelli-Szafran, C. E. The synthesis and structure-activity relationship of substituted N -phenyl anthranilic acid analogs as amyloid aggregation inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 654-657
28. Arumugan, K.; Subramanian, G. S.; Mallayasamy, S. R.; Averinemi, R. K.; Reddy, M. S.; Udupa, N. A study of rivastigmine liposomes for delivery into the brain through intranasal route Acta Pharm. 2008, 58, 287-297
29. Matsui, K.; Mishima, M; Nagai, Y.; Yuzuriha, T.; Yoshimura, T. Absorption, distribution, metabolism, and excretion of donepezil (Aricept) after a single oral administration to rat Drug Metab. Dispos. 1999, 27, 1406-1414
30. McNally, W. P.; Pool, W. F.; Sinz, M. W.; Dehart, P.; Ortwine, D. F.; Huang, C. C.; Chang, T.; Woolf, T. F. Distribution of tacrine and metabolites in rat brain and plasma after single- and multiple-dose regimens. Evidence for accumulation of tacrine in brain tissue Drug Metab. Dispos. 1996, 24, 628-633
31. Bounce, N. J.; Cater, S. R.; Scaiano, J. C.; Johnston, L. J. Photosubstitution of 1-methoxy-4-nitronaphthalene with amine nucleophiles: dual pathways J. Org. Chem. 1987, 52, 4214-4223
32. Glennon, R. A.; Naiman, N. A.; Pierson, M. E.; Smith, J. D.; Ismaiel, A. M.; Titeler, M.; Lyon, R. A. N -(Phthalimidoalkyl) derivatives of serotoninergic agents: a common interaction at 5-HT1A serotonin binding sites J. Med. Chem. 1989, 32, 1921-1926
33. Minetti, P.; Di Santo, R. Naphthyl Derivatives Inhibitors of beta-Amyloid Aggregation. International Patent Application WO2007045593, 2007.
34. Suzuky, H.; Nonoyama, N. Nitrogen dioxide-sodium iodide as an efficient reagent for the one pot conversion of aryl iodides under non aqueous conditions Tetrahedron Lett. 1998, 39, 4533-4536